Hikma Seeks To Meet Demand For 503B Compounding In US
CEO Sets Out Strategy For Company’s New Sterile Injectable Compounding Unit
Hikma has set out its expectations for a “gradual ramp-up” of the 503B sterile injectable compounding business that it has launched in the US this month, with CEO Siggi Olafsson explaining in detail the strategic rationale for the new business.
